Terms ending in 2041
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,939,319 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 11,976,056 | Substituted Alkoxypyridinyl Indolsulfonamides In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 12,179,128 | Hplc-Based Detection of Flocculation Agents in a Protein Sample In force · High confidence | Ucb Biopharma SRL | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.